MedTrace Logo

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

NCT04656431 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-02-09

No results posted yet for this study

Summary

This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating response to treatment.

Conditions

  • Primary CNS Lymphoma

Interventions

DRUG

Hyperpolarized pyruvate (13C)

Given intravenously (IV) injection prior to imaging

PROCEDURE

Magnetic resonance imaging (MRI)

MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • James Rubenstein

    lead OTHER

Principal Investigators

  • James Rubenstein, MD, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2025-03-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656431 on ClinicalTrials.gov